CTOs on the Move

54gene

www.54gene.com

 
54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.54gene.com
  • 1100 15th Street North West
    Washington, DC USA 20005
  • Phone: n/a

Executives

Name Title Contact Details

Funding

54gene raised $15M on 04/14/2020

Similar Companies

Bio-Circle

Bio-Circle is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synageva BioPharma

Synageva BioPharma Corp. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SciMetrika

SciMetrika is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apeel Sciences

We use our natural plant-based technologies to protect crops and harvested produce, helping to eliminate food spoilage and reduce reliance on chemicals. Accomplishing our mission means we will waste less food, water and energy, helping to preserve our natural ecosystems while creating economic opportunities for the 500 million small family farms worldwide. In the future, less food will be wasted, we will use smarter, more natural methods for growing and protecting crops, and there will be an abundance of fresh food for everyone.

Avalyn Pharma

Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.